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In this study, we identified specific carbapenemase-producing isolates applying an easy and 
rapid protocol for the detection of mature KPC-2 β-lactamase by MALDI-TOF MS from 
colony and positive blood culture bottles. In addition, we evaluated the correlation of the 
~11,109 Da signal as a biomarker associated with KPC-2 production. A collection of 126 
well-characterized clinical isolates were evaluated (including 60 KPC-2-producing strains). 
Presence of KPC-2 was assessed by MALDI-TOF MS on protein extracts. Samples were 
prepared using the double layer sinapinic acid technique. In order to identify mature KPC-
2, raw spectra were analyzed focusing on the range between m/z 25,000–30,000 Da. A 
single distinctive peak, at approximately m/z 28,544 Da was found in all clinical and 
control KPC-2-producing strains, and consistently absent in the control groups (ESBL 
producers and susceptible strains). This peak was detected in all species independently of 
where the gene blaKPC-2 was embedded. Statistical results showed 100% sensitivity, CI95%: 
[94.0%; 100%] and 100% specificity, CI95%: [94.6%; 100%], indicating a promising test 
with a high discriminative power. KPC-2 β-lactamase could be directly detected from both 
colonies and blood culture bottles. On the other hand, the m/z 11,109 Da signal determinant 
was only associated with 32% of Klebsiella pneumoniae and Escherichia coli KPC positive 
isolates. This MALDI-TOF MS methodology has the potential to detect directly the 
widespread and clinically relevant carbapenemase, KPC-2, in Enterobacterales with a 
straightforward, low cost process, assuming MALDI-TOF MS is already adopted as the 





















Resistance to carbapenems is one of the most relevant problems in current 
antimicrobial therapy for Gram-negative infections, limiting effective antimicrobial options 
and often leading to treatment failures (Ventola, 2015). 
Class A carbapenemases are among the relevant resistance mechanisms in clinical 
isolates of Enterobacterales; KPC-2 is distributed in all continents, including community 
settings (van Duin and Doi, 2017). Coding genes for the major allelic variants of these β-
lactamases are commonly carried on plasmids, with diversity being an important 
contributory factor for their spread (Cai et al., 2008, Giakkoupi et al., 2011, Gutkind et al., 
2013, Navon-Venezia et al., 2006). 
One of the key factors involving critical patients´ survival is a timely decision for an 
effective treatment, as delays may reduce the survival chances as much as 10 % daily (Luna 
et al., 2006). Therefore, among WHO recommendations, improvement (and acceleration) of 
diagnostic procedures is clearly needed (as an example, a dedicated call for better diagnosis 
is requested by the EU (https://www.jpiamr.eu/coming-soon-call-for-diagnostics-and-
surveillance-africa-and-asia/). So, rapid and specific methods for carbapenemase detection 
in clinical microbiology are desirable in order to avoid treatment failure and prevent 
dissemination events (Rhodes et al., 2017). 
Nowadays, preliminary screening for carbapenemase producers in clinical specimens is 
based on phenotypic tests. Traditional microbiological methods such as double disk 
synergy tests using β-lactam and β-lactamase-inhibitor disks, growth-based assays like 
modified Hodge test, and even the epsilometer tests (E-tests), remain convenient, easy to 
perform, but not fast methods for detecting these β-lactamase in Gram-negative bacilli 
(around 24-48 h after microorganism isolation). Manual and automated determination of 
minimal inhibitory concentration (broth microdilution assay and Phoenix or VITEK, 
respectively) are also reliable methods. Besides being time-consuming, some traditional 
microbiological methods have disadvantages such as interpretation difficulty and variability 
in the sensitivity/specificity parameters among different species (AlTamimi et al., 2017) 
Other phenotype-based assays are available, including, immunochromatographic assays 












Direct, and Blue-Carba) (Lima-Morales et al., 2018, Nordmann et al., 2012, Wareham et 
al., 2018). Also, polymerase chain reaction (PCR) used to confirm the presence of these 
resistance markers, is quite expensive (Mirande et al., 2015) and requires at least 3 h to 
obtain the results.  
One approach that may shorten the time-to-result for antibiotic susceptibility testing is 
matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF 
MS). Incorporation of MALDI-TOF MS has been one of the most significant breakthrough 
technologies included in modern clinical microbiology, and is today routinely used in 
medium and high complexity laboratories for rapid species identification (Sandalakis et al., 
2017). 
Current studies demonstrate the possibility to apply a MALDI-TOF MS approach to 
predict β-lactamase production based on the detection of hydrolyzed β-lactam substrates. 
Although reliable, this detection is laborious. β-lactam hydrolysis is evaluated after at least 
one hour incubation of the bacteria in presence of a suitable substrate (Hooff et al., 2012, 
Oviano et al., 2016, Sparbier et al., 2012). Following this procedure, enzyme detection is 
feasible and reflects the presence of one or more enzymes with hydrolytic activity on the 
provided substrate. 
Direct detection of a specific enzyme by analysis of the MALDI-TOF MS generated 
protein profile has been the subject of research in different studies. Among them, 
Papagiannitsis et al. detected CMY-2 enzyme in different enterobacteria after extraction of 
periplasmic proteins using a multiple steps procedure (Hart et al., 2015, Papagiannitsis et 
al., 2014). More recently, Espinosa et al. could detect a peak corresponding to CMY-2, 
analyzing the spectrum of proteins directly obtained from cellular lysates of Escherichia 
coli and other enterobacteria which displayed resistance to third generation cephalosporins 
(Espinosa et al., 2018).  
Antibiotic resistance has also been predicted by MALDI-TOF MS by detection of 
biomarkers associated with a specific resistance determinant. The p019 protein, linked to 
the plasmid located Tn4401a, present in KPC-2 producing Klebsiella pneumoniae ST 258, 
can be detected as a 11,109-Da peak in MALDI-TOF MS and was used to predict KPC 












Thus, prediction of this marker depends upon the surrounding genetic context, and as 
epidemiology of endemic or hyperendemic clones may vary across time and regions,  
detection of mature β-lactamase by MALDI-TOF MS, directly associated with the 
resistance pattern of bacteria, could be considered a more reliable marker. 
Enterobacterales may account for up to 30% bloodstream infections (Tariq and Rasool, 
2016). As reported by Kumar et al., if an ineffective treatment is applied in patients with 
septic shock, the mean survival rate decreased 7.6% per hour delayed (Kumar et al., 2006). 
The development of more rapid techniques for the prompt and accurate detection of 
resistance markers in the clinical laboratory should guide appropriate treatments. 
The aim of this study was to apply an easy and quick methodology for the detection of 
mature KPC-2 β-lactamase by MALDI-TOF MS directly on Gram-negative bacilli, 
focusing on Enterobacterales. In addition, the correlation of the ~11,109 Da signal as a 
biomarker associated with the KPC-2 production was evaluated and the possibilities for 
direct KPC-2 detection from positive blood culture bottles by MALDI-TOF MS were 
analyzed.  
2.   Materials and methods 
2.1 Control Strains 
Recombinant and transformant strains expressing KPC-2 were used as controls. 
To construct the recombinant plasmid, full-length blaKPC-2 (882 bp) was amplified by 
PCR using custom designed primers KPC-2F (5´-
TACGCGTCGACATGTCACTGTATCGCCGTC-3´) and KPC-2R (5´-
CCGGAATTCTTACTGCCCGTTGACGCC-3´) containing SalI and EcoRI restriction 
sites, respectively. The SalI–EcoRI blaKPC-2 fragment was cloned into the pK19 vector 
(recombinant plasmids pKPC-2-4), transformed in E. coli TOP10 (E. coli TOP10/pKPC-2-
4) and selected on Tryptic Soy Agar (TSA) containing 1 µg/ml imipenem (Sigma-Aldrich, 
USA). Recombinant plasmid was confirmed by sequencing.  
A wild-type plasmid carrying the blaKPC-2 and blaCTX-M-14 genes obtained from a 












E. coli blaKPC-positive transformant strains were selected on Mueller Hinton (MH) 
(Britania, Argentina) agar plates containing 1 µg/ml meropenem (Sigma-Aldrich). 
The MALDI-TOF MS spectra range to detect the KPC-2 enzyme was specially focused 
in the range between m/z 25,000–30,000 Da based on the theoretical mass of mature KPC-2 
protein. 
2.2 Strain collection 
A panel of 126 previously characterized isolates deposited in our laboratory collection 
in Buenos Aires, Argentina, was used. There was no epidemiological link among them. All 
bacteria were identified by MALDI-TOF MS (Bruker Daltonics, Germany) following the 
standard procedure (Matsuda et al., 2012). Sixty KPC-2-producing clinical isolates 
(Klebsiella pneumoniae (39), Enterobacter cloacae (7), Escherichia coli (4), Serratia 
marcescens (4), Citrobacter braakii (1) and Pseudomonas aeruginosa (5)) and 66 KPC-2-
negative isolates were included. In addition to being the most commonly isolated species, 
the KPC-2-producing K. pneumoniae isolates also corresponded to multiple different ST 
that were  circulating in our region (Table 1 and 2). 
2.3 Antimicrobial susceptibility and genetic characterization 
All isolates were previously characterized phenotypically by disk diffusion and synergy 
tests according to the Clinical and Laboratory Standards Institute (CLSI) guidelines (CLSI, 
2018). Production of carbapenemases was investigated using boronic acid and EDTA by 
synergy tests (Lee et al., 2001, Tsakris et al., 2009). Further genotypic characterization was 
carried out by PCR focused on different β-lactamase gene families. PCR amplifications 
were performed on total DNA using primers and conditions described previously 
(Dominguez et al., 2018). Amplicons were sequenced on both strands using an ABI3730XL 
DNA sequencer (Table 1 and 2).  
2.4 Bacterial typing  
K. pneumoniae ST-258 clone was characterized  by the pilv-l PCR amplification (Adler 
et al., 2014) while other STs were determined by the multilocus sequence typing (MLST) 
scheme (Diancourt et al., 2005). Characterization of the O25b-ST131 clone of E. coli was 












al., 2009). The genetic environment of the blaKPC-2 gene (isoforms of Tn4401) was explored 
by mapping as described previously (Cuzon et al., 2010, Kitchel et al., 2009, Naas et al., 
2008) (Table 1). In order to evaluate the presence of the p019 gene (which encodes for a 
hypothetical protein named p019) in the blaKPC-producing strains, a simple PCR was 
performed using custom designed primers (p019F: 5´- AATATTGATACTGACCGC-3´ 
and p019R: 5´- AACCCATTTTTGCATCTG-3´) which rendered an amplicon of 328 bp. 
2.4 Protein extraction protocol for β-lactamase detection by MALDI-TOF MS  
Pure cultures were obtained on MH agar plates without antibiotics and incubated 
overnight at 37 °C. Samples were prepared using a modified extraction protocol for β-
lactamase detection (formic acid- isopropyl alcohol – water, 17:33:50 ratio by volume), as 
previously described (Espinosa et al., 2018).  
2.5 Detection of mature KPC-2 protein from colonies 
The protein extraction with an organic solvent mentioned above was performed on 
colonies. The samples were loaded once in three different spots on the stainless steel 
MALDI target plate using the double layer sinapinic acid technique. Every spot was 
measured in duplicate (6 spectra per sample). Mass spectra were obtained using a Microflex 
LT mass spectrometer by flexControl 3.4 software (Bruker Daltonics, Germany) within the 
mass range of 17,000 to 50,000 Da as previously described (Espinosa et al., 2018). Data 
were automatically acquired using the AutoXecute acquisition control software (Bruker 
Daltonics) and spectra were analyzed using flexAnalysis 3.4 software. 
2.6 Detection of hypothetical p019 protein (~11,109 Da peak) by MALDI-TOF MS 
Detection of the ~11,109 Da peak was carried out in the 2,000 – 20,000 Da range for 
all 126 isolates. Briefly, one µl of the protein extraction for β-lactamase detection was 
applied in triplicate onto a MALDI target, the dried spots were overlaid with 1 µl of HCCA 
matrix (10 mg/ml α-cyano-4-hydroxy-cinnamic acid) (Bruker Daltonics) and acquired 
twice for a total of six spectra (Centonze et al., 2018, Youn et al., 2016). An external 
Standard BTS (Bruker Daltonics) was used for mass calibration during parameter 
optimization. Spectra were generated on a Microflex LT (Bruker Daltonics) MALDI-TOF 
MS system operated in linear mode with a total of 240 laser shots. Data acquisition and 












2.7 Detection of KPC-2 from blood culture (BC) bottles using MALDI-TOF MS 
Direct KPC-2 detection from positive blood culture bottles was performed on 39 
samples: 16 KPC-2-producing clinical isolates of K. pneumoniae (9), E. cloacae (1), E. coli 
(2), S. marcescens (3), and C. braakii (1); 23 non-KPC-2 producing clinical isolates were 
also included (Table 1). Briefly, 1 ml of a bacterial suspension (approximately 104 CFU) 
was inoculated in a pediatric blood culture bottle (BD BACTECTM Peds PlusTM/F Culture 
Vials, Argentina) previously inoculated with 5 ml of human blood. Blood cultures were 
incubated at 37 °C for 18 h. Direct KPC-2 detection was carried out using the protocol 
previously described (Espinosa et al., 2018). An extra-washing step with distilled water on 
the pellet was added prior to solvent extraction in order to remove cell debris. Samples 
were tested in triplicate using the double layer sinapinic acid technique as described above. 
2.8 Statistical analysis 
Spectra of each strain after automatic calibration and normalization were analyzed with 
the software ClinProTools 3.0 (Bruker Daltonics) (Ketterlinus et al., 2005). Statistical 
analysis was performed using the full raw spectra (17,000 to 50,000 Da) with the “Peak 
Statistic Calculation” tool. The area under the curve (AUC) of the ROC curve was 
evaluated for the specific peak (28,544 Da) between KPC-2 positive and negative strains, to 
establish the sensitivity, specificity and the discriminative power. 
2.9 Detection index 
The detection index (DI) was calculated for each isolate taking into account the peak 
intensities at 28,544 Da (PI28544 Da) as follows: DI = [PI28544 Da mean for each clinical 
isolate/PI28544 Da mean of 31 spectra of E. coli ATCC 25922]. E. coli ATCC 25922 spectra 
were used as the negative control. Data that did not follow a normal distribution, were 
presented as median and interquartile range. Also, 95% confidence intervals (CI95%) were 
calculated. Comparisons between groups were performed using the Mann-Whitney test 
(GraphPad Prism Version 5).  
2. Results and discussion 
The MALDI-TOF MS spectra range to detect the KPC-2 enzyme was modified, from 












between m/z 25,000–30,000 Da. E. coli TOP10 carrying the recombinant plasmid pK19-
KPC-2 (called pKPC-2-4) and their corresponding controls (E. coli TOP10 and E. coli 
TOP10 + pK19) were processed. A characteristic peak at around 28,544 Da (slightly 
differing from the expected value for the mature KPC-2 enzyme, i. e. without signal 
peptide, 28,477 Da) was only observed in the recombinant pKPC-2-4 strain (Figure 1a). In 
addition, the KPC-2 producing E. coli DH5α (electroporant) called TFI-KPC, displayed the 
same characteristic peak which was absent in the isogenic strain (E. coli DH5α) (Figure 
S1). These KPC-2-producing strains were used as positive controls each time when the 
different clinical isolates were analyzed. 
The protein extraction protocol for β-lactamase detection was conducted for all 126 
collection isolates included in the study. To confirm bacterial identification these extracts 
were assessed by MALDI-TOF MS using the standard procedure. Subsequently, all the 
protein extracts were analyzed by MALDI-TOF MS in order to detect the presence of KPC-
2. Comparison among mass spectral profiles showed that two groups could be 
differentiated after peak analysis. A single distinctive peak with different intensities, at 
approximately m/z 28,544 Da was found in all previously characterized KPC-2-producing 
Enterobacterales and was consistently absent in the KPC-2 negative isolates (Figure 1b). 
The presence of this distinctive peak was also observed in KPC-2-producing isolates of P. 
aeruginosa (Table 1 and Figure 1c). Analysis of replicate cultures of all isolates gave 
consistent and straightforward mass spectral profiles within this range. 
Thus, the visualization and identification of the 28,544 Da peak corresponding to the 
KPC-2 mature protein was successful using the supernatant obtained after applying the 































Figure 1. Peaks of MALDI-TOF mass spectra of the KPC-2 and non-KPC-2 producing 
strain. a) Peak detection of ~28,544 Da in E. coli with recombinant plasmid (E. coli TOP10 
+ pKPC-2-4) is indicated by red line; Absence of the ~28,544-m/z peak in the recipient 
strain (E. coli TOP10+pK19) is indicated by green line. Peak corresponding to KPC-2 is 
indicated with arrows. b) Spectra show the presence or absence of the KPC-2 peak in 
different Enterobaterales. Specific color (red, blue, light blue, magenta, and violet) was 
assigned to particular species (K. pneumoniae, E. cloacae, E. coli, S. marcescens, and C. 
braakii respectively). Green spectra correspond to non-KPC-2-producing strains 
(susceptible to β-lactams or TEM-1-, CMY-2- or CTX-M- producers). c) Dark blue spectra 
correspond to KPC-2 producing P. aeruginosa and green correspond to non-KPC-2-












from the intensities of the 28,544 Da peak in the KPC-2 and non-KPC-2 producing strains 
(red and green box, respectively). x and y axes show m/z values and intensity (in arbitrary 
units – a.u.), respectively. 
Statistical results showed a p-value < 0.000001 by Anderson-Darling test and 
Wilcoxon/Kruskal-Wallis test which confirmed a significant difference for the ~28,544 Da 
peak when both groups were compared (KPC-2 positive vs KPC-2 negative isolates) 
(Figure 1d). Consistently, the area under the curve (AUC) of the ROC curve for this 
specific peak was 1 (100% sensitivity, CI95%: [94.0%; 100%] and 100% specificity, 
CI95%: [94.6%; 100%]). It should be noted that representative isolates of the main K. 
pneumoniae sequence types which are disseminated worldwide were included (such as 
ST258, ST307, ST25, ST11, ST392, ST340, ST101, ST13) suggesting that this peak 
detection may be effective on different strains. Furthermore, the ~28,544 Da peak detection 
was useful on different species where KPC-2 is less frequent. 
The DI of KPC-2-producing isolates from colony assays varied between 171.3 - 12.0 
(median: 33.0, CI95%: [26.1; 39.9]) while for negative strains, between 5.0 - 0.2 (median: 
1.5, CI95%: [1.2; 1.7]) (Figure 2a). Values of this parameter could be used to define a cut-
off if it were possible to implement an automated procedure for the detection of clinically 
relevant β-lactamases.  
 
Figure 2. Box and whisker plot showing DI of KPC-2-producing strains (red) and non 
KPC-2-producing strains (green) (GraphPad Prism). The box always extended from the 












whiskers are drawn down to the 5th percentile and up to the 95th. Points below and above 
the whiskers – outliers - are drawn as individual points. p-value obtained with Mann-
Whitney test shows a significant difference between the two groups. a) Box-plot of DI from 
colony analysis.  b) Box-plot of DI from blood culture bottle analysis.  
Only eleven out of 39 KPC-2-producing K. pneumoniae (28%) were positive for the 
~11,109 Da peak and all of them were also positive for the p019 gene by PCR. All of these 
11 strains showed the presence of Tn4401 element corresponding to isoform a, and 10/11 
(91%) belonged to ST258 which was identified extensively worldwide (Table 1). The peak 
of ~11,109 Da was not observed in the rest of KPC-2 producing K. pneumoniae isolates 
(72%, 28/39). Four out of 28 isolates had Tn4401 (not isoform a) and three out of those 
four corresponded to the ST258 (Table 1). In the remaining isolates, blaKPC-2 was associated 
with a truncated structure of this transposon or to a non-Tn4401 element (NTE). 
Of the four KPC-2-producing E. coli clinical isolates (all characterized as ST131), two 
were positive for the ~11,109 Da peak coinciding with the presence of the p019 gene in the 
latter. As expected, Tn4401 (isoform a) was also detected in these two strains (Table 1). 
The remaining KPC-2 positive species (E. cloacae, S. marcescens, C. braakii and P. 
aeruginoasa) gave negative results for the ~11,109 Da peak, p019 gene and Tn4401. In 
these cases, blaKPC-2 would be associated with an NTE (Table 1). 
Detection of the ~11,109 Da peak was considered a promising test for the rapid 
detection of KPC-2-producing strains by MALDI-TOF MS (Gaibani et al., 2016, Youn et 
al., 2016).  In our study, the blaKPC-2 environment in the circulating strains showed a low 
prevalence of the p019 gene. This is not surprising considering that different genetic 
platforms can replace Tn4401, and the rearrangements that often occur in plasmids leads to 
the genetic evolution of these strains and the emergence of several successful clones. As 
previously reported, the p019 gene is part of the insertion sequence ISKpn31 which is 
inserted or is a constituent of the Tn4401a (Centonze  et al., 2018). In this study, blaKPC-2 
was not always associated with the Tn4401a isoform and was frequently associated with 
different environments. In good agreement with our results, previous research has also 
revealed that strains circulating in different regions possess various KPC environments 












considered a biomarker with low sensitivity in our region and others where the KPC-2 gene 
is embedded in diverse surrounding environments. 
In good agreement with our previous results, the distinctive peak of ~28,544 Da, 
corresponding to KPC-2 was visually observed in all spectra of KPC-2-producing isolates 
in the blood culture bottles tested, but not in the carbapenem-susceptible strains (Figure 
S2a). In order to validate this methodology in the clinical setting and estimate if the 
biomass present at the time the blood culture becomes positive allows for sufficient KPC-2 
detection, a trial with the participation of different laboratories will be necessary. Statistical 
results showed a 100% sensitivity and specificity (AUC: 1) (Figure S2b) with all included 
strains under the assayed conditions. Moreover, when the DI was evaluated in the blood 
culture bottles assays, KPC-2-producing isolates ranged between 118.1 – 9.3 (mean: 47.3, 
CI95%: [31.2; 63.4]) and the KPC-negative isolates between 2.4 - 0.1 (mean: 1.0, CI95%: 
[0.6; 1.2]) (Figure 2b). Presence of the biomarker (~11,109 Da peak) was also assessed 
directly from the blood culture bottles and it was detected only in the p019 positive isolates 
(3/16).   
One of the advantages of the use of MALDI-TOF MS for KPC-2 detection from colony 
or blood culture bottle is the substantial decrease in the turnaround time (TAT) compared to 
automated and traditional microbiological phenotypic methods. Although β-lactamase 
detection by ICAs display a shorter TAT (Riccobono et al., 2018) than MALDI-TOF MS 
resistance detection, the latter is a low cost procedure once the technology is in place (Tran 
et al., 2015). 
At the present time, any β-lactamase activity can be predicted using MALDI-TOF 
MS by detection of hydrolysis products of β-lactams. However, it is not possible to 
establish an accurate resistance profile, unless complementary hydrolysis tests with several 
substrates requiring 1 hour incubation time each are performed (Hooff et al., 2012, Sparbier 
et al., 2012). In this sense, the characterization of the resistance marker that is achieved 
with our protocol could be considered as another advantage. It is important to highlight 
that, beyond KPC-2, the procedure used in this work proved to be useful for the detection 
of different β-lactamases such as CMY-2 (Espinosa et al., 2018) and preliminarely on 












It is well known that colorimetric tests are easy to perform and cost-effective methods 
but, in contrast with our method, the identification of β-lactamases involved is not possible. 
Applying the proposed protocol using a single sample preparation method it was 
possible to carry out the bacterial identification (even the p019 resistance biomarker) and 
detection of KPC production, in less than 1 h (usually 30 minutes), employing the HCCA 
and SA matrices, respectively.   
 
3. Conclusions 
In this study, we demonstrated that MALDI-TOF MS is able to detect directly the most 
clinically relevant carbapenemase, the KPC-2-enzyme, on different Gram-negative bacilli, 
mainly Enterobacterales, both from colony material and directly from positive blood 
culture bottles, and at the same time that bacterial identification becomes available. The 
rapid and accurate detection of KPC-2, as well as any other relevant β-lactamase that are 
still being explored by MALDI-TOF and other techniques might have extensive clinical 
implications in resistance diagnosis, antibiotic stewardship for early infection treatment, 
and implementation of procedures aimed at carbapenem resistance containment. 
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Table 1. Characterization of KPC-2 producing strains.  
Strain Isolate Origen Resistance Marker 
Peak  at 
m/z 
~28,477 Da 










K. pneumoniae 720 Human/ Urine blaKPC-2/blaCTX-M-G1 (+) (-) (-) NTEKPC 340 
K. pneumoniae 952  Human/ Urine blaKPC-2/blaCTX-M-G1 (+) (-) (-) NTEKPC 340 
K. pneumoniae 729  Human/ Tracheal fluid blaKPC-2/blaCTX-M-2 (+) (-) (-) NTEKPC 340 
K. pneumoniae 139 Human/ Swab blaKPC-2 (+) (-) (-) NTEKPC 340 
K. pneumoniae 439  Human/ Swab blaKPC-2 (+) (-) (-) NTEKPC 340 
K. pneumoniae 176 Human/ Swab blaKPC-2/blaCTX-M-G1 (+) (-) (-) NTEKPC 340 
K. pneumoniae 791 Human/ Swab 
blaKPC-2/blaCTX-M-15/ blaTEM-1a/ 
blaOXA-1/ blaSHV-11 
(+) (-) (-) NTEKPC 340 
K. pneumoniae 069 Human/ Abdominar fluid blaKPC-2/blaCTX-M-G1 (+) (-) (-) NTEKPC 340 
K. pneumoniae 070 BC Human/ Liver abscess blaKPC-2/blaCTX-M-G1 (+) (-) (-) NTEKPC 340 
K. pneumoniae 805 Human/ Urine blaKPC-2/blaCTX-M-G1 (+) (-) (-) NTEKPC 340 
K. pneumoniae UTI-7 Human/ Blood 
blaKPC-2/blaCTX-M-15/blaTEM-1b 
blaSHV-11 
(+) (-) (-) NTEKPC 392 
K. pneumoniae 74I BC Human/ BAL blaKPC-2/blaCTX-M-2 (+) (-) (-) NTEKPC ND 
K. pneumoniae 197 BC Human/ Swab blaKPC-2/blaCTX-M-G1 (+) (-) (-) NTEKPC ND 
K. pneumoniae CX27 Human/ Urine blaKPC-2/blaCTX-M-G1/ blaCTX-M-2 (+) (-) (-) NTEKPC 11 
K. pneumoniae HJMC5
 BC
 Human/ Soft t issue blaKPC-2 (+) (+) (+) Yes
a
 258 
K. pneumoniae HSM 456 Human/ Urine blaKPC-2 (+) (-) (-) NTEKPC 25 
K. pneumoniae A12 BC Human/ Tracheal fluid blaKPC-2/blaCTX-M-G1 (+) (-) (-) NTEKPC SLV 13 
K. pneumoniae A24  BC Human/ Catheter blaKPC-2 /blaCTX-M (+) (-) (-) Yes
b
 258 
K. pneumoniae A23 Human/ Catheter blaKPC-2/blaCTX-M-G1 (+) (-) (-) NTEKPC SLV 13 
K. pneumoniae A25 Human/ Catheter blaKPC-2 /blaCTX-M (+) (-) (-) Yes
b
 258 
K. pneumoniae A27 Human/ Catheter blaKPC-2 /blaCTX-M (+) (-) (-) Yes
b
 258 
K. pneumoniae M1 Human/ Blood blaKPC-2 (+) (-) (-) NTEKPC 392 
K. pneumoniae M2 Human/ Blood blaKPC-2 (+) (+) (+) Yes
a
 258 
K. pneumoniae M3 Human/ Blood blaKPC-2 (+) (-) (-) NTEKPC 13 
K. pneumoniae M4 Human/ Blood blaKPC-2 (+) (-) (-) NTEKPC 392 
K. pneumoniae M5 Human/ Blood blaKPC-2 (+) (-) (-) NTEKPC 392 
K. pneumoniae M6 Human/ Blood blaKPC-2 (+) (+) (+) Yes
a
 101 
K. pneumoniae M7 Human/ Blood blaKPC-2 (+) (+) (+) Yes
a
 258 
K. pneumoniae M9 BC Human/ Soft t issue blaKPC-2 (+) (-) (-) NTEKPC 392 
K. pneumoniae M10 Human/ Urine blaKPC-2 (+) (-) (-) NTEKPC 392 





 Human/ Urine blaKPC-2 (+) (+) (+) Yes
a
 258 
K. pneumoniae M17 Human/ Urine blaKPC-2 (+) (-) (-) NTEKPC 392 
K. pneumoniae M22 Human/ Blood blaKPC-2 (+) (-) (-) Yes
b
 307 
K. pneumoniae M23 Human/ Abdominar fluid blaKPC-2 (+) (+) (+) Yes
a
 258 
K. pneumoniae 2-10 Human/ Urine blaKPC-2 (+) (+) (+) Yes
a
 258 
K. pneumoniae 16-10 Human/ BAL blaKPC-2 (+) (+) (+) Yes
a
 258 














Strain Isolate Origen Resistance Marker 
Peak  at 
m/z 
~28,477 Da 










K. pneumoniae 20-10 Human/ Urine blaKPC-2 (+) (+) (+) Yes
a
 258 
E. cloacae 680 BC Human/ Urine blaKPC-2/blaCTX-M-G1 (+) (-) (-) NTEKPC ND 
E. cloacae A26 Human/ Catheter blaKPC-2 /blaCTX-M-G9 (+) (-) (-) NTEKPC ND 
E. cloacae 016 Human/ Swab blaKPC-2 (+) (-) (-) NTEKPC ND 
E. cloacae 043 Human/ Swab blaKPC-2 (+) (-) (-) NTEKPC ND 
E. cloacae 21051 Human/ Swab blaKPC-2 (+) (-) (-) NTEKPC ND 
E. cloacae 029 Human/ Swab blaKPC-2 (+) (-) (-) NTEKPC ND 
E. cloacae 91051 Human/ Swab blaKPC-2 (+) (-) (-) NTEKPC ND 
E. coli 519 Human/ Soft t issue blaKPC-2/blaCTX-M-G9 (+) (+) (+) Yes
a
 131 
E. coli 151 BC Human/ Blood blaKPC-2 (+) (-) (-) NTEKPC 131 
E. coli 547 Human/ Soft t issues blaKPC-2/blaCTX-M-G9 (+) (+) (+) Yes
a
 131 
E. coli 075 BC Human/ Peritoneal fluid blaKPC-2 (+) (-) (-) NTEKPC 131 
S. marcescens AMP162-I BC Human/ Catheter blaKPC-2/blaCTX-M-2 (+) (-) (-) NTEKPC ND 
S. marcescens AMP162-II Human/ Catheter blaKPC-2/blaCTX-M-2 (+) (-) (-) NTEKPC ND 
S. marcescens Sm759 BC Human/ Blood blaKPC-2 (+) (-) (-) NTEKPC ND 
S. marcescens Sm216 BC Human/ Tracheal fluid blaKPC-2/blaCTX-M-2 (+) (-) (-) NTEKPC ND 
C. braakii Cbra007 
BC
 Human/ Urine blaKPC-2 (+) (-) (-) NTEKPC ND 
P. aeruginosa 2047 Human/ Nosocomial blaKPC-2 (+) (-) (-) NTEKPC 654 
P. aeruginosa 4270 Respiratory secretions blaKPC-2 (+) (-) (-) NTEKPC 654 
P. aeruginosa 4753 Respiratory secretions blaKPC-2 (+) (-) (-) NTEKPC 654 
P. aeruginosa Mart1 Human/ Nosocomial blaKPC-2 (+) (-) (-) NTEKPC ND 
P. aeruginosa 537 Human/ Nosocomial blaKPC-2 (+) (-) (-) NTEKPC ND 
E. coli DH5α Laboratory Strain gyrA96 (-) (-) (-) (-) n/a 
E. coli TFI-KPC (Tc) Laboratory Strain gyrA96/blaKPC-2/blaCTX-M-9 (+) (+) (+) Yes
a
 n/a 
E. coli TOP10 Laboratory Strain rpsL (-) (-) (-) (-) n/a 
E. coli TOP10 + pk19 Laboratory Strain rpsL/aph(3')-Ia (-) (-) (-) (-) n/a 
E. coli TOP10 + pKPC-2-4) (RC) Laboratory Strain blaKPC-2 /rpsL/aph(3')-Ia (+) (-) (-) (-) n/a 
NTEKPC: blaKPC-bearing partial or non-Tn4401 element,  
a
 Tn4401a isoform,  b Tn4401 isoform different to Tn4401a, BC Blood Culture assay strains, 




















Table 2. Characterization of non KPC-2 producing strains. 
Strain Isolate Origen Resistance Marker 
Peak  at  m/z 
~28,477 Da 




K. pneumoniae I26 BC Human/ Nosocomial blaCTX-M-G9 (-) (-) ND 
K. pneumoniae HAP13 Human/ Urine blaCTX-M-G2 (-) (-) ND 
K. pneumoniae HAP33 Human/ Urine blaCTX-M-G1 (-) (-) ND 
K. pneumoniae HAP121 Human/ Urine blaCTX-M-G1 (-) (-) ND 
K. pneumoniae B4 Human/ Nosocomial blaCTX-M-15 (-) (-) 11 
K. pneumoniae CM4 Human/ Nosocomial blaCTX-M-15 (-) (-) 11 
K. pneumoniae I3 BC Human/ Nosocomial blaCTX-M-15 (-) (-) 11 
K. pneumoniae I4 Human/ Nosocomial blaCTX-M-15 (-) (-) 11 
K. pneumoniae I11 Human/ Nosocomial blaCTX-M-G1 (-) (-) ND 
K. pneumoniae I17 BC Human/ Nosocomial blaCTX-M-G1 (-) (-) ND 
K. pneumoniae I21 BC Human/ Nosocomial blaCTX-M-G1 (-) (-) ND 
K. pneumoniae T8 Human/ Nosocomial blaCTX-M-15 (-) (-) 11 
K. pneumoniae C14 BC Human/ Nosocomial blaCTX-M-2 (-) (-) ND 
K. pneumoniae I18 BC Human/ Nosocomial blaCTX-M-2 (-) (-) ND 
K. pneumoniae N1 Human/ Nosocomial blaCTX-M-2 (-) (-) ND 
K. pneumoniae C10 BC Human/ Nosocomial blaCTX-M-2 (-) (-) ND 
K. pneumoniae CV1 BC Human/ Nosocomial blaCTX-M-2/blaCTX-M-15 (-) (-) 11 
K. pneumoniae CM1 Human/ Nosocomial blaCTX-M-2 (-) (-) 11 
K. pneumoniae I1 Human/ Nosocomial blaCTX-M-2 (-) (-) ND 
K. pneumoniae N2 BC Human/ Nosocomial blaCTX-M-2 (-) (-) ND 
K. pneumoniae Ck 
BC
 Human/ Nosocomial blaCMY-2 (-) (-) ND 
E. coli CM3 Human/ Nosocomial blaCTX-M-14 (-) (-) ND 
E. coli N8 Human/ Nosocomial blaCTX-M-14 (-) (-) ND 
E. coli C17 BC Human/ Nosocomial blaCTX-M-14 (-) (-) ND 
E. coli SM8 Human/ Nosocomial blaCTX-M-14 (-) (-) 68 
E. coli L4 
BC
 Human/ Nosocomial blaCTX-M-15 (-) (-) 131 
E. coli M1 Human/ Nosocomial blaCTX-M-15 (-) (-) 410 
E. coli N2 Human/ Nosocomial blaCTX-M-15 (-) (-) ND 
E. coli N4 Human/ Nosocomial blaCTX-M-15 (-) (-) 410 
E. coli SM5 BC Human/ Nosocomial blaCTX-M-15 (-) (-) 131 
E. coli T3 Human/ Nosocomial blaCTX-M-15 (-) (-) 131 
E. coli T1 Human/ Nosocomial blaCTX-M-15 (-) (-) 131 
E. coli V91 Pet/Cat  blaCTX-M-2 (-) (-) ND 
E. coli V109 Pet/Cat  blaCTX-M-2 (-) (-) ND 
E. coli 24-28 BC Human/ Nosocomial blaCTX-M-2 (-) (-) ND 
E. coli N1 BC Human/ Nosocomial blaCTX-M-2 (-) (-) ND 
E. coli Itu2 Human/ Urine blaCTX-M-2/mcr-1 (-) (-) ND 












Strain Isolate Origen Resistance Marker 
Peak  at  m/z 
~28,477 Da 




E. coli SM3 Human/ Nosocomial blaCTX-M-2 (-) (-) ND 
E. coli VTEM-38 Pet/Dog blaTEM-1 (-) (-) ND 
E. coli VTEM-86 Pet/Dog blaTEM-1 (-) (-) ND 
E. coli IACA17 Human/ Urine NDβ (-) (-) ND 
E. coli CEM4 Human/ Urine NDβ (-) (-) ND 
E. coli 1510 Human/ Urine blaCMY-2 (-) (-) ND 
E. coli 856 Human/ Abdominar fluid blaCMY-2 (-) (-) ND 
Cbra CX16 
BC
 Human/ Soft t issue NDβ (-) (-) ND 
Cbra HdeC2 
BC
 Human/ Urine NDβ (-) (-) ND 
Sm I2 
BC
 Human/ Nosocomial blaCTX-M-2 (-) (-) ND 
Sm T9 
BC
 Human/ Nosocomial blaCTX-M-2 (-) (-) ND 
Sm 947 
BC
 Human/ ND blaSME- 1 (-) (-) ND 
Sm CAR653 Human/ Soft t issue NDβ (-) (-) ND 
Sm CX46 Human/ Soft t issue NDβ (-) (-) ND 
Sm CX17 
BC
 Human/ Soft t issue NDβ (-) (-) ND 
Sm HdeC30 Human/ Tracheal fluid NDβ (-) (-) ND 
Sm HAP54 Human/ Bile NDβ (-) (-) ND 
Sm SOA15 Human/ Blood NDβ (-) (-) ND 
Sm VSm102 Pet/Dog NDβ (-) (-) ND 
Sm VSm117 Pet/Dog NDβ (-) (-) ND 
Ecl 1042 
BC
 Human/ Blood act7 /blaTEM-1 (-) (-) ND 
Ecl I28 Human/ Nosocomial blaCTX-M-15 (-) (-) ND 
Ecl V206 Pet/Cat  Ind AmpC (-) (-) ND 
Ecl V211 Pet/Cat  NDβ (-) (-) ND 
Ecl V207 
BC
 Pet/Dog blaCTX-M-15 (-) (-) ND 
P. aeruginosa 24 Human/ Nosocomial NDβ (-) (-) ND 
P. aeruginosa 2054 Human/ Nosocomial NDβ (-) (-) ND 
P. aeruginosa ATCC 9027 Laboratory Strain NDβ (-) (-) ND 
BC
 Blood Culture assay strains, blaCTX-M-G1, blaCTX-M-G2 and blaCTX-M-G9: correspond to blaCTX-M gene group 1, 2 or 9, respectively, NDβ: 



















 KPC-2-enzyme was detected by MALDI-TOF MS in different Gram-negative 
bacilli 
 
 A distinctive peak around 28,544 Da was found in all KPC-2 producers 
 
 Direct KPC-2 detection on positive blood culture bottles was also achieved 
 
 The proposed accompanying 11,109 Da peak was a bad predictor for KPC-2 
presence  
ACCEPTED MANUSCRIPT
